Almost as quickly as Covid-19 erupted in early 2020, so too did the rush to find drugs, either old or new, to treat the contagion spreading around the world. Although researchers soon identified some that quelled late-stage symptoms or weakly restrained the virus, Paxlovid, a pill from Pfizer Inc. that prevents severe disease, appears poised to take a solid lead in the lucrative coronavirus treatment market.
Yet an important component of Pfizer’s antiviral has links to a drug from rival Merck & Co.: boceprevir, developed decades ago to fight hepatitis C. That fragment accounts for at least 20% of Paxlovid’s coronavirus-fighting power—and perhaps much more—researchers estimate, and a key patent on the molecule it comes from resides with Merck.
Several labs have noted the potential of boceprevir, a protease inhibitor that Merck sold earlier under the brand name Victrelis. But as developers at universities began looking for ways to use it and similar compounds to make Covid drugs over the past two years, Merck sat on the sidelines.
Bypassing the drug while a rival seems set to profit handsomely from one of its key parts adds to Merck’s saga of Covid futility. Along with Sanofi and GlaxoSmithKline Plc, Merck is among the big drugmakers that have failed to devise a usable coronavirus vaccine in the world’s biggest infectious disease crisis in a century and partake in a market for Covid shots that health analytics firm Airfinity Ltd. estimates will be worth $85 billion this year.
Denne historien er fra February 07, 2022-utgaven av Bloomberg Businessweek.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent ? Logg på
Denne historien er fra February 07, 2022-utgaven av Bloomberg Businessweek.
Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.
Allerede abonnent? Logg på
Instagram's Founders Say It's Time for a New Social App
The rise of AI and the fall of Twitter could create opportunities for upstarts
Running in Circles
A subscription running shoe program aims to fight footwear waste
What I Learned Working at a Hawaiien Mega-Resort
Nine wild secrets from the staff at Turtle Bay, who have to manage everyone from haughty honeymooners to go-go-dancing golfers.
How Noma Will Blossom In Kyoto
The best restaurant in the world just began its second pop-up in Japan. Here's what's cooking
The Last-Mover Problem
A startup called Sennder is trying to bring an extremely tech-resistant industry into the age of apps
Tick Tock, TikTok
The US thinks the Chinese-owned social media app is a major national security risk. TikTok is running out of ways to avoid a ban
Cleaner Clothing Dye, Made From Bacteria
A UK company produces colors with less water than conventional methods and no toxic chemicals
Pumping Heat in Hamburg
The German port city plans to store hot water underground and bring it up to heat homes in the winter
Sustainability: Calamari's Climate Edge
Squid's ability to flourish in warmer waters makes it fitting for a diet for the changing environment
New Money, New Problems
In Naples, an influx of wealthy is displacing out-of-towners lower-income workers